| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Email: |
ordercn@merckgroup.com |
| Products Intro: |
Product Name:Compound 8918
CAS:65009-19-0
|
|
| | PptT inhibitor 8918 Basic information |
| Product Name: | PptT inhibitor 8918 | | Synonyms: | PptT inhibitor 8918;Urea, N-(2,6-diethylphenyl)-N'-[(ethylamino)iminomethyl]-;Compound 8918 | | CAS: | 65009-19-0 | | MF: | C14H22N4O | | MW: | 262.35 | | EINECS: | | | Product Categories: | | | Mol File: | 65009-19-0.mol |  |
| | PptT inhibitor 8918 Chemical Properties |
| density | 1.11±0.1 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | DMSO: 2mg/mL, clear | | pka | 17.94±0.70(Predicted) | | form | powder | | color | white to beige |
| | PptT inhibitor 8918 Usage And Synthesis |
| Biological Activity | Compound 8918 is an orally active, non-cytotoxic, phosphopantethein (Ppt)-binding pocket-targeting, non-competitive M. tuberculosis (Mtb) Ppt transferase (PptT) inhibitor (IC50 = 2.5 μM, Emax 80-90%) th at exhibits mycobactericidal activity (MIC90 = 0.56-3 μM/29 clinical Mtb isolates; MBC99 = 6.25 μM/Mtb, 3.13 μM/M. smegmatis) with no bactericidal potency against S. aureus, E. coli, P. aeruginosa, Streptomyces or C. albicans. Oral administration is efficacious against H37Rv replication in mouse lung in vivo (by 100%; 100 mg/kg/d, 4 d/wk for 2 wks). Mutations in MtbH37Rv rv2794c (PptT) or rv279c (Ppt hydrolase, PptH) gene confers 8918 resistance. |
| | PptT inhibitor 8918 Preparation Products And Raw materials |
|